Claim your bonus gift: give any amount to get 4 KaiPA coasters! Donate today

Unhealthy report for Zetia and Vytorin

Jennifer Collins Nov 16, 2009
HTML EMBED:
COPY

Unhealthy report for Zetia and Vytorin

Jennifer Collins Nov 16, 2009
HTML EMBED:
COPY

TEXT OF STORY

Bill Radke:A new study is raising more questions about Merck’s cholesterol drugs. The results were presented yesterday at the annual meeting of the American Heart Association. Marketplace’s Jennifer Collins reports.


Jennifer Collins: The study compared Merck drug Zetia to another drug, Niaspan. That’s made by rival Abbott Laboratories, and Abbott sponsored this study.

Researchers found that Zetia didn’t shrink the plaque in some arteries as much as Niaspan did. Zetia users may also have suffered more heart attacks. That may not exactly prompt you to:

ZETIA AD: Ask your doctor if Zetia’s right for you.

And may make you more likely to ask for Niaspan. Analyst Les Funtleyder of Miller Tabak says that’s exactly what the study was designed to do:

LES FUNTLEYDER: It sort of is a marketing study. You want to prove your drug is better than the other drug.

Trouble is, this is yet another in a string of unfavorable results for Zetia. Prescription rates of the drug have already fallen more than 20 percent.

Funtleyder: The question is how much worse it gets.

Experts also say the study is too small to draw firm conclusions. Larger studies are in the works, but results won’t be known for several years.

I’m Jennifer Collins for Marketplace.

As a nonprofit news organization, our future depends on listeners like you who believe in the power of public service journalism.

Your investment in Marketplace helps us remain paywall-free and ensures everyone has access to trustworthy, unbiased news and information, regardless of their ability to pay.

Donate today — in any amount — to become a Marketplace Investor. Now more than ever, your commitment makes a difference.